The global Acellular Dermal Matrices Market is estimated to be valued at US$ 8.8 Bn or Mn in 2023 and is expected to exhibit a CAGR of 12.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Acellular dermal matrices are used for tissue repairs and regeneration. They help restore damaged or weakened soft tissues like skin and organs by providing structural support. Some key advantages are reduced scarring, faster healing and customized sizing for different wounds and tissue defects. The growing prevalence of burns, injuries and soft tissue defects is driving the need for acellular dermal matrices.
Market key trends:
3D bioprinting of tissues and organs is a major trend in the market. It involves layer-by-layer deposition of biomaterials, growth factors, and living cells to fabricate 3D functional living tissues and organ constructs. Companies are developing innovative 3D bioprinting technologies using patient-specific structural and cellular information from medical imaging technologies to develop bio-printed dermal matrices tailored for individual tissue regeneration needs. This reduces healing time and scarring for patients.
The global acellular dermal matrices market is dominated by the alloderm segment, accounting for over 35% of the total market share. Alloderm is a type of acellular dermal matrices made from human tissue that acts as a scaffold for tissue regeneration. It is widely used in breast reconstruction procedures, as it provides strength and structure to the breast while allowing for tissue ingrowth. The application of alloderm results in more natural breast shape and appearance compared to other reconstruction methods. Its availability as both meshes and sheets also provides more flexibility to surgeons in terms of size and area of breast coverage.
The global Acellular Dermal Matrices Market is expected to witness high growth, exhibiting a CAGR of 12.1% over the forecast period, due to increasing breast reconstruction procedures globally.
The US dominates the global acellular dermal matrices market currently, accounting for over 40% of the total market share. This is attributed to the high number of breast reconstruction procedures performed in the country annually. The Asia Pacific region is expected to exhibit the fastest growth over the coming years driven by large patient populations and increasing access to advanced medical treatments.
Key players operating in the acellular dermal matrices market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.